Assessing ISUP prostate cancer grade groups in patients treated with definitive dose escalated external beam radiation.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
09 2021
Historique:
received: 21 02 2021
revised: 14 06 2021
accepted: 15 06 2021
pubmed: 26 6 2021
medline: 3 11 2021
entrez: 25 6 2021
Statut: ppublish

Résumé

The five grade group system has been validated for men treated with radical prostatectomy. However, the prognostic value for men treated with radiation therapy is uncertain, with prior studies utilising old techniques and doses. We aimed to validate the International Society of Urological Pathology (ISUP) groupings for men treated with contemporary radiation therapy. Men with localised prostate cancer treated with image-guided, dose-escalated (≥78 Gy) external beam radiation were identified across four institutions. Primary outcome was time to biochemical failure. Harrell's C index assessed performance of the ISUP system against other grading stratifications. 2205 men were included, withmedian follow-up of 5.6 years. Seven-year actuarial rates of biochemical failure for grade groups 1-5 were 9.3%, 10.4%, 13.2%, 12.4% and 23.4%. On multivariate analysis, hazard ratios for biochemical failure were1.19, 1.00, 1.10, 1.05 and 2.10 for grade groups 1-5, relative to 2. P values were only significant for grade group 5. Harrell's C index favoured an alternative three group model (comprising Gleason scores [6 and 3 + 4 = 7] vs [4 + 3 = 7 and 8] vs [9 and 10]) over ISUP grade groups. The ISUP grade groups were not validated in a contemporary cohort treated with dose-escalated, image-guided radiation therapy. Grade groups 1-4 were not statistically different from each other; however, grade group 5 had a significantly worse prognosis. We identified a new three group model that better predicted biochemical outcomes. Further work is requiredto validate optimal groupings for modern radiation therapy and investigate the contrasting prognostic capability of grade groups in surgical and radiation therapy patients.

Identifiants

pubmed: 34171454
pii: S0167-8140(21)06608-1
doi: 10.1016/j.radonc.2021.06.025
pii:
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

91-97

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Jonathan Toby (J)

Central Coast Cancer Centre, Gosford, Australia. Electronic address: jonathan.toby@health.nsw.gov.au.

Thomas Eade (T)

Central Coast Cancer Centre, Gosford, Australia; Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Australia; University of Sydney Northern Clinical School, Kolling Building Level 7, Royal North Shore Hospital, St Leonards, Australia.

George Hruby (G)

Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Australia; University of Sydney Northern Clinical School, Kolling Building Level 7, Royal North Shore Hospital, St Leonards, Australia.

Andrew Kneebone (A)

Central Coast Cancer Centre, Gosford, Australia; Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Australia; University of Sydney Northern Clinical School, Kolling Building Level 7, Royal North Shore Hospital, St Leonards, Australia.

Noel Aherne (N)

Mid North Coast Cancer Institute Coffs Harbour, Coffs Harbour Health Campus, Coffs Harbour, Australia.

Chris Brown (C)

Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Australia; National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Camperdown, Australia.

Lesley Guo (L)

Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Australia.

Matthew Hoffmann (M)

Mid North Coast Cancer Institute Port Macquarie, Port Macquarie Health Campus, Port Macquarie, Australia.

Thomas P Shakespeare (TP)

Mid North Coast Cancer Institute Coffs Harbour, Coffs Harbour Health Campus, Coffs Harbour, Australia; Mid North Coast Cancer Institute Port Macquarie, Port Macquarie Health Campus, Port Macquarie, Australia; North Coast Cancer Institute, Lismore Cancer Care and Haematology Unit, Ground Floor, Lismore, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH